IPO registrations (S-1, F-1) · Registrants
ILLUMINA, INC.
- SEC CIK
- 1110803 · filings on EDGAR ↗
- Name on the registration
- ILLUMINA INC
- Former names
- ILLUMINA INC (2000–2019)
- Registration
- Form S-1, first filed 2000-04-03, last 2000-07-27; 1 initial registration, 6 amendments
- Outcome
- Final prospectus filed 2000-07-28
- Industry (SIC)
- Laboratory Analytical Instruments 3826
- Incorporated in
- DE
- Business address
- 5200 ILLUMINA WAY, San Diego, CA 92122
- EIN
- 33-0804655
- Ticker
- ILMN (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ILLUMINA, INC. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2000-07-27)
- Final price
- $16.00 per share, above the range (424B4 filed 2000-07-28, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $96,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ILMN
- Lead underwriters
- Goldman Sachs (2,551,200 shares); Cowen (1,274,400 shares); J.P. Morgan (1,274,400 shares)
- Syndicate
- Hambrecht & Quist; BofA Securities (120,000); Bear Stearns (120,000); A.G. Edwards (120,000); Edward D. Jones & Co., L.P (120,000); Lehman Brothers (120,000); Baird (60,000); William Blair (60,000); Legg Mason (60,000); Ramirez & Co. (60,000); Sutro & Co. Incorporated (60,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ILLUMINA, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Illumina Inc. Fuzzy (name and state)
- Business registration: Illumina, Inc. Fuzzy (name and state)
- Business registration: ILLUMINA, INC Fuzzy (name and state)
- Business registration: ILLUMINA, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: ILLUMINA, INC. EXACT (EIN (EXACT))
- Federal award recipient: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying client: ILLUMINA, INC. Fuzzy (name and state)
- Lobbying registrant: ILLUMINA, INC. Fuzzy (name and state)
- SEC filer: ILLUMINA INC EXACT (CIK (EXACT))
- Person page: Robert S Epstein Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-04-03 | S-1 | S-1 (registration) | ILLUMINA INC | 0001012870-00-001863 ↗ |
| 2000-07-03 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001012870-00-003639 ↗ |
| 2000-07-10 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001021408-00-002143 ↗ |
| 2000-07-19 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001072993-00-000523 ↗ |
| 2000-07-26 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001012870-00-003960 ↗ |
| 2000-07-27 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001012870-00-003981 ↗ |
| 2000-07-27 | S-1/A | S-1/A (amendment) | ILLUMINA INC | 0001072993-00-000539 ↗ |
| 2000-07-28 | 424B4 | 424B4 (final prospectus) | ILLUMINA INC | 0001012870-00-004000 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2000-07-27 | S-1/A | registration statement | $13.00–$15.00 | 6,000,000 | - | Nasdaq ILMN | 4 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 3 | document ↗ | |
| 2000-07-28 | 424B4 | final prospectus | $16.00 | 6,000,000 | $96,000,000 | Nasdaq ILMN | 14 | primary document; price sentence, shares headline, proceeds table, underwriting table 13, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| STUELPNAGEL JOHN R | Director,Officer | Sr VP and COO; Sr VP of Operations & COO | 29 | 2006–2008 | |
| WALT DAVID R | Director | 338 | 2006–2016 | ||
| FLATLEY JAY T | Director; Director,Officer; Officer | CEO; CEO and Chairman of the Board; Chief Executive Officer; President and CEO; President & CEO; President & CEO Officer | 343 | 2006–2021 | |
| CABRAL PAULETTE D | Officer | Vice President Human Resources | 1 | 2006 | |
| HENRY CHRISTIAN O | Officer | CFO, VP Finance; EVP & Chief Commercial Officer; Senior VP and CFO; Sr VP and GM; Sr VP and GM Genomic Solutions; Sr VP & CFO; Sr VP & Chief Commercial Ofcr; Sr VP & Chief Commercial Offic; Sr VP, General Manager Genomic; Sr VP & GM Genomic Solutions; Sr VP, GM Genomic Solutions; Sr VP, GM Life Science; Sr VP, GM Life Sciences & CFO; SVP and CFO; SVP, Chief Commercial Officer; SVP/GM Genomic Solutions | 121 | 2006–2017 | |
| ORPIN TRISTAN | Officer | EVP Clinical Genomics; Sr VP & Chief Commercial Off.; Sr VP & Chief Commercial Offcr; Sr VP & Chief Commercial Offic; Sr VP, Commercial Operations; Sr VP of Commercial Operations; SVP & Chief Commercial Officer; VP Worldwide Sales; VP Worldwide Sales Officer | 121 | 2006–2016 | |
| Holden Arthur | Officer | Sr. VP Corp and Market Dev; Sr VP Corp & Market Dev | 3 | 2006–2007 | |
| Cabou Christian | Officer | Senior VP, General Counsel; Sr VP and General Counsel; Sr. VP and General Counsel; Sr VP Gen Counsel & Secretary; Sr VP & General Counsel; Sr. VP, General Counsel | 52 | 2006–2013 | |
| BRADBURY DANIEL | Director | 89 | 2006–2017 | ||
| EASTHAM KARIN | Director | 38 | 2006–2019 | ||
| GRINT PAUL C | Director | 14 | 2006–2013 | ||
| RASTETTER WILLIAM H | Director | 35 | 2006–2016 | ||
| GOLDSTEIN JACK | Director | 9 | 2006–2010 | ||
| BOWMAN A BLAINE | Director | 47 | 2007–2018 | ||
| West John | Officer | Chief Executive Officer; Sr VP & GM DNA Sequencing; Sr VP & GM, DNA Sequencing; Sr. VP & GM DNA Sequencing | 21 | 2007 | |
| WHITFIELD ROY A | Director | 41 | 2007–2016 | ||
| Heath Gregory | Officer | Sr. VP and GM, Diagnostics; Sr VP & General Manager | 33 | 2008–2013 | |
| McComb Joel | Officer | Sr. VP and GM, Life Sciences; Sr VP & General Manager | 5 | 2008–2010 | |
| Ronaghi Mostafa | Officer | Sr Vice President & CTO; Sr VP Chief Technology Officer; Sr VP & CTO; SVP & CTO; SVP, Entrepreneurial Devlopmt | 78 | 2008–2020 | |
| MOELLER GERALD | Director | 23 | 2010–2015 | ||
| Naclerio Nicholas | Officer | Sr VP, Corp Develop & GM; Sr VP, Corp Development; Sr VP, Corporate Development; Sr VP, Corporate & Venture Dev; Sr VP & General Manager; SVP Corporate Development; SVP Corp & Venture Development | 49 | 2011–2016 | |
| Stapley Marc | Officer | CFO; EVP & Chief Administrative Ofc; EVP Strategy & Corp Developmt; Sr VP & CFO | 67 | 2012–2019 | |
| Posard Matthew L. | Officer | Sr VP & General Manager; Sr VP & GM, Consumer Genomics | 8 | 2012–2013 | |
| Bianchi Paul L | Officer | Sr VP Human Resources; Sr VP, Human Resources; Sr. VP, Human Resources | 24 | 2012–2016 | |
| Lewis Mark L | Officer | Sr VP & General Manager; Sr VP & GM Molecular Biology; SVP & GM Molecular Biology | 10 | 2012–2013 | |
| EPSTEIN ROBERT S | Director | 47 | 2012–2025 | person page Fuzzy | |
| Bouchard Michel | Officer; Other | Chief Accounting Officer; VP, Finance; VP, Finance & Chief Accounting | 60 | 2013–2017 | |
| Dadswell Charles | Officer | Sr VP & General Counsel; SVP & General Counsel; SVP, General Counsel | 114 | 2013–2024 | |
| Klausner Richard | Officer | Sr VP, Chief Medical Officer | 11 | 2013–2016 | |
| deSouza Francis A | Director,Officer; Officer | President; President and CEO | 67 | 2013–2023 | |
| Huber Jeff | Director | 11 | 2014–2017 | ||
| OSTADAN OMEAD | Officer | EVP Ops, Products, Strategy; Sr VP Product Dev & Operations; SVP Mktg, Prod & Strat Plan | 50 | 2015–2020 | |
| ARNOLD FRANCES | Director | 20 | 2016–2025 | ||
| SCHILLER PHILIP W | Director | 14 | 2016–2026 | ||
| SAMAD SAM | Officer | Sr. VP and CFO; SVP and CFO | 25 | 2017–2022 | |
| DORSA CAROLINE | Director | 16 | 2017–2026 | ||
| Hampton Malcolm Garret | Officer | EVP Clinical Genomics Group; SVP Clinical Genomics Group | 8 | 2017–2020 | |
| THOMPSON JOHN WENDELL | Director | 7 | 2017–2022 | ||
| Van Oene Mark | Officer | SVP Chief Commercial Officer | 29 | 2017–2020 | |
| MCGINNIS KAREN K | Officer | VP, Chief Accounting Officer | 16 | 2017–2021 | |
| GUTHART GARY S | Director | 12 | 2017–2025 | ||
| Hoyt Aimee L | Officer | SVP, Chief People Officer | 30 | 2018–2023 | |
| RAGUSA ROBERT P | Officer | SVP, Global Quality & Ops | 14 | 2019–2021 | |
| SIEGEL SUSAN E | Director | 10 | 2019–2026 | ||
| GOSWAMI JOYDEEP | Officer | SVP Chief Financial Officer; SVP, Chief Financial Officer; SVP Corp Business Development | 17 | 2019–2024 | |
| Febbo Phillip G. | Officer | SVP Chief Medical Officer | 18 | 2019–2023 | |
| TOUSI SUSAN H | Officer | SVP, Chief Commercial Officer; SVP Product Development | 52 | 2019–2023 | |
| Gottlieb Scott | Director | 15 | 2020–2026 | ||
| Aravanis Alexander | Officer | SVP, Chief Technology Officer | 17 | 2020–2023 | |
| Reeves Kathryne Gambrell | Officer | SVP, Chief Marketing Officer | 12 | 2020–2024 | |
| TORRES JOSE | Officer | VP, Chief Accounting Officer | 4 | 2021–2022 | |
| Pegels Kevin Carl | Officer | Chief of Global Operations | 18 | 2021–2026 | |
| Rollins Carissa | Officer | SVP, Chief Information Officer | 11 | 2022–2025 | |
| Frank John Edward | Officer | Chief Public Affairs Officer | 4 | 2022–2023 | |
| Ericksen Scott D | Officer | VP, Chief Accounting Officer | 14 | 2022–2026 | |
| Teno Andrew | Director | 2 | 2023 | ||
| MACMILLAN STEPHEN P | Director | 3 | 2023–2024 | ||
| Ullem Scott B. | Director | 16 | 2023–2026 | ||
| Barnard Steven | Officer | SVP, Chief Technology Officer | 15 | 2023–2026 | |
| Thaysen Jacob | Director,Officer | Chief Executive Officer | 12 | 2023–2026 | |
| Leckman Patricia | Officer | SVP, Chief People Officer | 12 | 2024–2026 | |
| Dhingra Ankur | Officer | SVP, Chief Financial Officer | 5 | 2024–2026 | |
| Wedel Christensen Jakob | Officer | SVP, Strategy/Corp Development | 11 | 2024–2026 | |
| RICHO ANNA | Director | 4 | 2024–2026 | ||
| Cunningham Everett | Officer | SVP, Chief Commercial Officer | 4 | 2024–2025 | |
| Davies Scott M | Officer | Chief Legal Officer; Interim General Counsel | 15 | 2024–2026 | |
| Meister Keith A. | Director | 14 | 2025–2026 | ||
| KING DAVID P | Director | 2 | 2026 | ||
| Skovronsky Daniel | Director | 2 | 2026 | ||
| Sullivan Michael C | Officer | Chief Commercial Officer | 2 | 2026 | |
| Coletti Julie Ann | Officer | Chief Legal Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Illumina Inc. | CA | State business registries | name and state |
| Business registration | Illumina, Inc. | CA | State business registries | name and state |
| Business registration | ILLUMINA, INC | CA | State business registries | name and state |
| Business registration | ILLUMINA, INC. | CA | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | ILLUMINA, INC. | CA | State business registries | name and state |
| Contractor | ILLUMINA INC | CA | Nonprofit contractors (Form 990) | name and state |
| Federal award recipient | ILLUMINA, INC. | CA | Federal spending (USAspending) | name and state |
| Lobbying registrant | ILLUMINA, INC. | CA | Federal lobbying (LDA) | name and state |
| Paying company | Illumina, Inc. | CA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Illumina, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | ILLUMINA, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Illumina, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | ILLUMINA, INC. | EIN (EXACT) | ||
| Lobbying client | ILLUMINA | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | ILLUMINA, INC. | Federal lobbying (LDA) | name and state | |
| Person page | Robert S Epstein | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Laboratory Analytical Instruments, CA first:
- NGEN, INC. CA
- CEPHEID CA
- LJL BIOSYSTEMS INC CA
- AGILENT TECHNOLOGIES, INC. CA
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CA
- QPC Lasers CA
- WaferGen Bio-systems, Inc. CA
- PROTEINSIMPLE CA
- Bionano Genomics, Inc. CA
- AutoGenomics, Inc. CA
In other datasets, the same topic (Technology) in CA:
- Lobbying client: 8X8, INC. (Federal lobbying (LDA))
Interests: Laboratory Analytical Instruments · Technology